作者
Peter Ueda, Björn Pasternak, Björn Eliasson, Ann-Marie Svensson, Stefan Franzén, Soffia Gudbjörnsdottir, Kristian Hveem, Christian Jonasson, Mads Melbye, Henrik Svanström
发表日期
2019/6/1
期刊
Diabetes Care
卷号
42
期号
6
页码范围
e92-e94
出版商
American Diabetes Association
简介
Post hoc analyses of the Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN-6) showed an increased risk of diabetic retinopathy complications associated with semaglutide versus placebo among patients with a history of retinopathy, especially among those with insulin use (1). Although concerns have been raised regarding the safety of glucagon-like peptide 1 (GLP-1) receptor agonists in patients with existing retinopathy, subgroup analyses by retinopathy status at baseline have not been presented for other trials of GLP-1 receptor agonists; the two observational studies on GLP-1 receptor agonists and diabetic retinopathy performed to date have excluded patients with a history of retinopathy (2) or treatment of retinopathy (3). We conducted a cohort study (January 2010 to December 2016) of patients with existing retinopathy using …
学术搜索中的文章
P Ueda, B Pasternak, B Eliasson, AM Svensson… - Diabetes Care, 2019